Case Presentation: Relapsed/Refractory Multiple Myeloma
Patient Case:
Background:
A 65-year-old African American man with hypertension, hyperlipidemia, and autoimmune thyroiditis was referred in November 2021 for evaluation of suspected multiple myeloma. Evaluation of mildly elevated creatinine revealed an IgA kappa paraprotein of 5.2 g/dL, with hemoglobin 8.6 g/dL. He also reported right shoulder pain, initially attributed to exercise, but orthopedic imaging revealed lytic lesions. Additional studies showed hemoglobin 7.6 g/dL, total protein 11.2 g/dL, albumin 2.9 g/dL, M-spike 5.88 g/dL, IgA 5.2 g/dL, free kappa 125, free lambda 3, and a kappa/lambda ratio of 40. PET-CT demonstrated innumerable osteolytic lesions, many FDG avid, and bone marrow biopsy showed approximately 90% plasma cell infiltration. FISH was positive for deletion 13q and trisomies 3, 7, 9, and 17, consistent with hyperdiploidy, without high-risk translocations or deletions. He was classified as ISS and R-ISS stage II.
He began daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVd) in March 2022, followed by autologous stem cell transplantation with melphalan 200 mg/m² on June 24, 2022, as well as lenalidomide maintenance. Day 100 restaging demonstrated a deep response, with an undetectable paraprotein, IgA 23 mg/dL, less than 5% plasma cells in the marrow, and no FDG-avid myelomatous lesions on PET-CT.
Relapse:
In December 2023, approximately 18 months after transplant, the patient sustained a left humeral fracture while lifting his grandchild and underwent surgical fixation in January 2024. PET-CT in February 2024 showed new and enlarging FDG-avid lytic lesions, and marrow biopsy demonstrated approximately 40% plasma cell involvement. IgA increased to 3,203 mg/dL with a free kappa/lambda ratio of 30.77.
Management:
He began carfilzomib, daratumumab, and dexamethasone (Car/Dara/Dex) in February 2024, with a marked biochemical response, but concern remained regarding disease in the left arm. CAR-T therapy was discussed for durable disease control; however, he was not ready to proceed because treatment would require an extended absence from work.
He was subsequently diagnosed with stage IIC, Grade Group 3 prostate cancer and completed radiation therapy in March 2025. A February 2025 marrow biopsy showed less than 5% plasma cells without a monotypic population by flow cytometry, although the specimen was hemodilute and suboptimal. Given his preference to defer CAR-T, he transitioned to daratumumab and pomalidomide in March 2025. His paraprotein became undetectable by May 2025 and remains undetectable as of September 2026, with a normalized free kappa/lambda ratio of 1.29. He remains on Dara/Pom, with CAR-T reserved for future progression.


